Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for ...
The Trump Administration has designed a Most-Favored-Nation (MFN) drug pricing policy framework to address the major differences in drug prices and contributions to the pharmaceutical innovation ...
Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump on Aug. 31 announced deals with another nine pharmaceutical manufacturers, bringing to 26 the total number ...
The latest agreements involve Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. President Donald Trump has expanded his push to lower ...
About a quarter of the drugs launched last year had an annual net price exceeding $500,000 — part of a trend in which ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. President Trump announced new tariffs on generic drugs, effective August 1, 2026, starting ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Chris Klomp, a key architect of the administration's Most-Favored Nation drug pricing policy ...
Although nearly half of all U.S. hospitals participate in it, few Americans have heard of the 340B Drug Pricing Program. The ...
The U.S. Food and Drug Administration's human drug enforcement program is substantially larger, broader in scope, and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results